Other /

What is TRACLEER used for?

What is TRACLEER used for?

Bosentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1).

What are the side effects of TRACLEER?

Common side effects of Tracleer include:

  • dizziness,
  • flushing,
  • upset stomach,
  • fatigue,
  • tiredness,
  • headache,
  • swelling of the feet/ankles/legs, or.
  • itching.

Is TRACLEER generic?

Hikma is introducing bosentan tablets, in dosage strengths of 62.5 mg and 125 mg. The product is the generic of Actelion’s Tracleer. Bosentan is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and to decrease clinical worsening.

What is the cost of TRACLEER?

The cost for Tracleer oral tablet 62.5 mg is around $6,081 for a supply of 30, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. A generic version of Tracleer is available, see bosentan prices.

Does Tracleer lower blood pressure?

Tracleer lowers blood pressure in your lungs, helping your heart pump blood more efficiently. Tracleer is used to treat pulmonary arterial hypertension (PAH) in adults and children who are at least 3 years old. It improves your ability to exercise and prevents your condition from getting worse.

What class of drug is Tracleer?

Bosentan is in a class of medications called endothelin receptor antagonists. It works by stopping the action of endothelin, a natural substance that causes blood vessels to narrow and prevents normal blood flow in people who have PAH.

What does bosentan treat?

Bosentan is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs) in adults and children 3 years of age and older. Bosentan may improve the ability to exercise and slow the worsening of symptoms in patients with PAH.

Who is the manufacturer of Tracleer?

SOUTH SAN FRANCISCO, Calif, September 6, 2017 – Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for TRACLEER® (bosentan) for use in pediatric patients …

Is there a generic for bosentan?

May 9, 2019 – Amneal and Par/Endo launched AB-rated generic versions of Actelion’s Tracleer (bosentan) 62.5 mg and 125 mg tablets.

What is the cost of bosentan?

The cost for bosentan oral tablet 62.5 mg is around $1,196 for a supply of 60 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.

How long can you take bosentan?

For oral dosage forms (tablets or tablets for oral suspension): For pulmonary arterial hypertension: Adults—At first, 62.5 milligrams (mg) two times a day (morning and evening) for 4 weeks. Your doctor may increase your dose up to 125 mg two times a day.

What is tractracleer used for?

TRACLEER is a prescription medicine indicated for patients with certain types of pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the vessels of the lungs.

How do I start a patient on Tracleer ®?

Once the prescription is written, the healthcare team must complete all the forms necessary to start the patient on TRACLEER ®. The Bosentan REMS Program was designed to manage serious risks associated with TRACLEER ®.

Can Tracleer be reintroduced in adults?

There is no experience with the reintroduction of Tracleer in these circumstances. in adults and pediatric patients >12 years and >40 kg, reduce the daily dose to 62.5 mg twice daily or interrupt treatment, and monitor aminotransferase levels at least every 2 weeks.

Does Tracleer cause peripheral edema?

Peripheral edema is a known clinical consequence of PAH and worsening PAH and is also a known effect of Tracleer and other endothelin receptor antagonists. In PAH clinical trials with Tracleer, combined adverse events of fluid retention or edema were reported in 1.7% (placebo-corrected) of patients.